NeuroSense Therapeutics Reports Mid-Year Financials
Company Announcements

NeuroSense Therapeutics Reports Mid-Year Financials

Neurosense Therapeutics Ltd. (NRSN) has released an update.

NeuroSense Therapeutics Ltd. has reported a decrease in total assets from $3,185,000 to $1,841,000 within the first half of 2024, reflecting a significant drop in cash and cash equivalents. The company’s net loss widened to $6,261,000 for the six months ended June 30, 2024, compared to the same period in the previous year. Despite a challenging period, NeuroSense continued to raise capital through the issuance of shares, bringing in a net amount of $4,209,000.

For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskNeuroSense Therapeutics Secures Continued Nasdaq Listing
TipRanks Auto-Generated NewsdeskNeurosense Therapeutics Secures $30 Million Equity Deal
TipRanks Auto-Generated NewsdeskNeuroSense Completes Key ALS Trial Phase
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App